You are invited to attend Keck Graduate Institute’s Focus Track Friday Business of Bioscience on Friday, December 2, 2011.
While, the initial sessions are mainly of interest to business focus track students, all students are encouraged to attend the sessions about the future of pharmaceuticals and biotechnology.
We are pleased to welcome Dr. Stephen Eck, VP of Astellas (and former VP of Eli Lilly and Pfizer). Stephen will be talking about "Genomics, Market Segmentation and the Implications for the Pharmaceutical Industry." After lunch, Ryan Bethencourt, Joel Dudley and Raymond McCauley will be discussing their current startup efforts in a panel entitled “Open, cheap and fast: New models of biotechnology entrepreneurship.”
Please note that the agenda is subject to change. A final agenda will be available at check-in.
8:30—9:00 am: Check-in
9:00—9:15 am: Welcome and Opening Remarks
Dr. Sheldon M. Schuster, President; KGI
Dr. Joel West, Professor, Innovation & Entrepreneurship and Focus Track Champion-Business of Bioscience; KGI
9:30—10:30 am and 10:45—11:45 am: Career Workshops
(Business Development, Operations, and Project Management)
11:45—1:15 pm: Lunch and Keynote Speaker
“Genomics, market segmentation and the implications for the pharmaceutical industry”
Therapeutics have historically targeted broad classes of diseased and patients. Today, the existing approaches are reaching their limits. At the same time, genomics medicine is being used to isolate disease subsets and treat specific patients. Diagnosing, proscribing, and delivering such personalized medicines will dramatically change the roles of physicians and pharmacists, and will also require transforming the distribution channels used to deliver these medicines
Stephen Eck, Vice President of Oncology Medical Sciences; Astellas Pharma Global Development
1:30—2:45 pm: Open, Cheap, and Fast: New Models of Biotechnology Entrepreneurship
The rapid fall in computing prices represented by Moore’s Law unleashed a wave of IT entrepreneurship from 1990-2010. Today, dramatic cost reductions in genomics, outsourcing, open data and falling IT costs are enabling new models of biotech startups
Ryan Bethencourt, Director of Business Development; Parexel
Joel Dudley, Co-Founder and Director of Informatics, NuMedii
Raymond McCauley, Chief Sciences Officer; Genomeria
Moderated by: Ujval Kondragunt, MBS ’13; KGI
3:00—4:30 pm: Reception
When & Where
Keck Graduate Institute